Novel Prostaglandin D Synthase Inhibitors Generated by Fragment-Based Drug Design

Citations Over TimeTop 10% of 2008 papers

Abstract

We describe the discovery of novel inhibitors of prostaglandin D2 synthase (PGDS) through fragment-based lead generation and structure-based drug design. A library of 2500 low-molecular-weight compounds was screened using 2D nuclear magnetic resonance (NMR), leading to the identification of 24 primary hits. Structure determination of protein-ligand complexes with the hits enabled a hit optimization process, whereby we harvested increasingly more potent inhibitors out of our corporate compound collection. Two iterative cycles were carried out, comprising NMR screening, molecular modeling, X-ray crystallography, and in vitro biochemical testing. Six novel high-resolution PGDS complex structures were determined, and 300 hit analogues were tested. This rational drug design procedure culminated in the discovery of 24 compounds with an IC 50 below 1 microM in the in vitro assay. The best inhibitor (IC 50 = 21 nM) is one of the most potent inhibitors of PGDS to date. As such, it may enable new functional in vivo studies of PGDS and the prostaglandin metabolism pathway.

Related Papers

• → Mechanisms of Action for Small Molecules Revealed by Structural Biology in Drug Discovery(2020)91 cited
• → Active site binding modes of the β-diketoacids: a multi-active site approach in HIV-1 integrase inhibitor design(2004)56 cited
• → Characterization of a Tyrosyl Radical in Prostaglandin Endoperoxide Synthase-2(1994)46 cited
• → Evidence for exchange of inhibitors which bind to the active site of trypsin(1981)5 cited
• → HARIBOSS: a curated database of RNA-small molecules structures to aid rational drug design(2022)1 cited